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Abstract
Background. The aim of this study was to assess whether rubella vaccination immedi-
ately after delivery could expose seronegative women to specific untoward effects.
Methods. 163 rubella-seronegative women received Measles-Mumps-Rubella (MMR) 
vaccine in the immediate postpartum period; they were evaluated at one month and 
at three months thereafter through telephone interviews. As controls, we matched 163 
rubella-seropositive women, who might experience similar symptoms for any reason in 
the same timeframe. 
Results. No relevant difference was still observed in the frequency of arthralgia and 
myalgia at one and three months. Instead, a statistically significant difference in the fre-
quency of cervical lymphadenopathy and cutaneous rash at one month (p = 0.028 and p 
= 0.005, respectively), was observed between cases and controls. However, no statistical 
differences were reported at three months for the same symptoms.
Conclusions. Postpartum rubella vaccination with MMR is safe and advisable to avoid 
congenital rubella syndrome.
INTRODUCTION
Rubella is a febrile rash illness caused by rubella virus 
in susceptible children and adults. Its public health threat 
resides in the potentially devastating effects during preg-
nancy, especially in the first trimester: it can indeed result 
in miscarriage, fetal death, or congenital malformations, 
known as congenital rubella syndrome (CRS) [1]. 
In Italy, statutory notification of rubella cases has 
been activated in 1970. Notification data have shown 
recurrence of epidemics every 4-5 years until 1997, 
when the last outbreak of the nineties occurred; sub-
sequently, the incidence of rubella remained low until 
the epidemic 2002-2003, and another outbreak was re-
ported in 2008, with > 5000 notified cases [2, 3].
In 2003, Italy adhered to the WHO’s European re-
gional goal of achieving elimination of measles and 
rubella and prevention of congenital rubella infection 
by 2010 [4], and a National Plan for the elimination 
of measles and congenital rubella was approved (Piano 
Nazionale per l’Eliminazione del Morbillo e della Rosolia 
Congenita, PNEMoRc) [5]. Although progresses were 
made, the goal was not achieved by 2010, and the target 
date was deferred to 2015 [6]; consequently, the Italian 
National Plan (INP) was renewed until 2015 [3]. The 
data collected during the period 2012-2015 detected by 
the PASSI system (Progressi nelle Aziende Sanitarie per 
la Salute in Italia), indicate that the goal has not been 
reached. The percentage of women of childbearing age 
susceptible to rubella is currently 2%; however, fairly 
high percentage of women, around 37%, is not aware of 
their immune status [7].
It has been estimated that, in order to achieve the 
complete elimination of CRS, the percentage of wom-
en of childbearing age susceptible to rubella infection 
should be < 5% [3]. For this reason, the INP recom-
mends rubella serology test for women with childbear-
ing potential and subsequent vaccination of those who 
are found seronegative or without written record of 
vaccination; as well as vaccination immediately upon 
completion or termination of their pregnancy and be-
fore discharge from the hospital of all women found 
susceptible during pregnancy [5].
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Rubella-susceptible women who are not vaccinated 
because they are or may be pregnant should be coun-
selled about the potential risk for CRS and the impor-
tance of being vaccinated as soon as they are no longer 
pregnant [8].
We are still far from achieving the goal, despite the 
progress made. Even if they are not notified probable or 
confirmed cases of congenital rubella by 2015 [9], it is 
necessary to strengthen the active offer of the vaccine, 
even in the postpartum and postabortum. 
The time after delivery and before discharge from the 
hospital is an ideal time to administer live and attenu-
ated vaccines. Indeed, women who plan to breastfeed 
may receive vaccination, as no evidence exists for any 
risk due to rubella vaccine while breastfeeding. It would 
be appropriate to create a database of women who re-
fuse vaccination in the first instance, in order to make a 
motivational recall later on. 
Monovalent rubella vaccine has been widely used 
in the past and it has also been associated to differ-
ent adverse events in the general population [11-16]. 
The main adverse consequences described involved the 
musculoskeletal system (arthralgia and myalgia) and 
neurological system (paresthesias) [14, 17, 18]. More-
over, Tingle et al. have shown that postpartum adminis-
tration of monovalent rubella vaccine is responsible for 
a significantly higher incidence of acute joint manifes-
tations than placebo administration (30% vs 20%) [19]. 
Minor side effects may be experienced by children after 
MMR vaccination, including fever, malaise and cuta-
neous rash 5-21 days after the first vaccination (10%) 
and arthralgia (3%), lasting 18 days on average [20, 21] 
Incidence rates of arthritis and arthralgia are generally 
higher in women than in children (12-26% vs 0-3%), and 
the reaction tends to be more severe and longer [22, 
23]. About 25% of non-immune, post-pubertal women 
reported joint pain after receiving rubella vaccine, and 
10-30% also arthritis-like signs and symptoms [19, 24]. 
These reactions are generally well-tolerated and rarely 
interfere with daily activities [25]: anaphylaxis is indeed 
extremely rare [26]. 
The aim of this study was to investigate the incidence of 
arthralgia and arthritis in women vaccinated in the imme-
diate post-partum period as compared to already immune 
women, who may experience similar symptoms for any 
other reason, because the joint pain in one of the most 
frequently reported side effects in literature [11-16].
MATERIALS AND METHODS
This was a case-control study of women who gave birth 
at Castelli Hospital in Verbania and at SS. Pietro e Paolo 
Hospital in Borgosesia, (Piedmont region, Italy), be-
tween January 2011 and December 2014. Serology test 
for rubella was performed in all women during the first 
trimester of pregnancy. A commercial enzyme-linked 
immunosorbent assay (ELISA) kit (Enzygnost Anti-
Rubella-Virus/IgG, Dade Behring, Marburg, Germany) 
was used. Rubella-susceptible women received a single 
dose of MMR vaccine (MMR VAXPRO, Sanofi Pasteur 
MSD) during the 24-48 hours following delivery.
Case-control matching was based on rubella seropos-
itive women (as controls) who gave birth immediately 
after each enrolled case according to the same delivery 
procedure: vaginal delivery vs caesarean section. 
Exclusion criteria were age < 18 years, contraindi-
cation to immunization, current immunosuppressive 
therapy or serious illnesses, and any immunodeficiency.
Before MMR vaccine administration, patients re-
ceived counselling about the potential risks and ben-
efits of the intervention, and signed informed consent 
to vaccination and follow-up evaluation. Institutional 
review board consent was waived, as treatment was 
considered routine clinical practice at our institution 
and in agreement with national recommendations.
Age, parity, current or former medications, underly-
ing diseases, results of diagnostic tests, history of allergic 
reactions, and previous post-vaccine complications were 
collected for each woman participating in the study.
Short-term complications were defined as events that 
occurred within the first 28 days from vaccine admin-
istration. Long-term complications were defined as 
events that occurred from 28 days after vaccination un-
til the end of the follow-up.
After discharge, patients were evaluated at one 
month and three months after vaccination. Follow-up 
consisted of a telephone interview aimed at determin-
ing the state of subjective well-being or the experience, 
if any, of musculoskeletal complications.
Statistical analysis was performed with 2 x 2 table us-
ing OpenEpi® software.
RESULTS
One hundred-seventy-one seronegative women were 
asked to participate (142 in Verbania and 29 in Borgo-
sesia). Of these, 163 were enrolled in the study. Three 
refused to be enrolled but nonetheless accepted to 
get vaccinated (1 in Verbania and 2 in Borgosesia), 5 
women refused both, stating as a reason to refuse the 
case Wakefield [27] despite the scientific community 
uncovered the intellectual fraud [28, 29], in total they 
were enrolled for the study 163 cases and 163 controls, 
matched by mode of delivery: 72% spontaneous deliv-
ery, 18% caesarean section. At one-month follow up, 
162 women in the case group and 161 women in the 
control group agreed upon answering our telephone in-
terview; at three month follow-up, 154 women in the 
case group and 159 women in the control group an-
swered, total loss of subjects during the follow-up was 
13 (9 cases and 4 controls). Failure to answer the tele-
phone interview brought to exclusion from the study. 
Nearly 15% (24/163) of the cases the sample was not 
at first pregnancy and a substantial proportion was of 
North African origin (37/163); furthermore, at one 
month follow-up 83% of women who received vaccina-
tion exclusively breastfed their infants, compared with 
89% of women who did not. At three months, percent-
ages dropped to 78% and 82%, respectively; socio-de-
mographic characteristics of subjects are summarized 
in Table 1. At one month follow-up, arthralgia occurred 
in 17 cases (10.4%) and 14 controls (8.6%) (p = 0.29; 
OR 1.23 [95% CI 12.58 - 2.63]) (Table 2). No difference 
was reported between the two groups in the frequency 
of acute myalgia (p = 0.19), acute paresthesia (p = 0.15) 
or pharyngitis (p = 0.32). However, the difference in the 
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frequency of cervical lymphadenopathy and cutaneous 
rash between the two groups was statistically significant 
(p = 0.028 and p = 0.005, respectively). A three-month 
follow-up, the difference in the frequency of cervical 
lymphadenopathy and cutaneous rash was no longer 
observed (p = 0.19 and p = 0.27, respectively); arthral-
gia was present in 11 cases (7.1%) and 8 controls (5%) 
(p = 0.21; OR 1.45 [CI 0.56 - 3.87]. No difference was 
reported in the frequency of myalgia (p = 0.15), pares-
thesia (p = 0.15), and pharyngitis (p = 0.34). Overall, 
the frequency of chronic adverse reactions is summa-
rized in Table 3.
DISCUSSION
Several national and international health authorities 
promoted awareness campaigns aimed at reducing the in-
cidence of rubella. In Italy, the National Plan for the Elim-
ination of Measles and Congenital Rubella PNEMoRc 
has set goals of reaching a vaccination coverage rate for 
MMR vaccine ≥ 95%, and of reducing the percentage 
of rubella-susceptible women of childbearing age to less 
than 5% [3]. However, the changing scenario of resident 
population in our country may hamper achieving these 
targets in the future. Indeed, the increasing number of 
immigrants and refugees hosted or rescued entails that 
a large part of this new population coming from low-in-
come countries could likely have skipped national vaccine 
campaigns (if any), thus enabling recirculation of rubella 
virus among susceptible subjects [30-32].
Immediate postpartum (and postabortum) could be 
therefore an additional opportunity to intercept suscep-
tible women and then to lessen the likelihood of new 
outbreaks; however, robust data about safety and ef-
fectiveness of rubella vaccine at this time point are still 
lacking [33]. 
The side effects of vaccination may be a cause of re-
jection, especially in mothers who are breast feeding. 
Interestingly, we found no difference between cases 
and controls with respect to the onset of arthralgia 
and myalgia after vaccination. We also found a statisti-
cally significant difference in the frequency of cervical 
lymphadenopathy and skin rash at one month, but not 
at three months. Moreover, the rash indicated by re-
spondents (cases) was only limited to the inoculation 
area, while in the controls it was on the face. 
Moreover, at three month follow-up, incidence of 
arthralgia and myalgia was not statistically significant 
between the two groups either. 
Another advantage could be that rubella vaccina-
tion has not been shown to interfere with breastfeeding 
(Table 1). 
Our study has some limitations: the first is the sample 
size that cannot be considered an expression of the gen-
eral population. Furthermore, the analyzed sample was 
not referred to clinical evaluation, but only to telephone 
interview to assess our hypothesis. The second is that the 
Table 1
Demographic characteristics of the study population
Vaccination No vaccination
N = 163 (%) N = 163 (%)
Age (years)
18 - 23 21 (12.8) 31 (19)
24 - 29 49 (30) 38 (23.3)
30 - 35 89 (54.6) 92 (56.4)
36 - 41 4 (2.4) 2 (1.2)
Ethnic origin
Italy 107 (65.6) 111 (68)
Est Europe 9 (5.5) 3 (1.8)
North Africa 37 (22.6) 41 (25.1)
Oriental 7 (4.2) 6 (3.6)
Other 3 (1.8) 2 (1.2)
Obstetric history
Nulliparous 139 (85.2) 143 (87.7 )
Primiparous 17 (10.4 ) 9 (5.5 )
Multiparous 7 (4.2) 11 (6.7 )
Breastfeeding at 1 month
Exclusive 83% 89%
Mixed 4% 1%
Artificial 13% 10%
Breastfeeding at 3 months
Exclusive 78% 82%
Mixed 5% 9%
Artificial 17% 9%
Table 2
Follow-up results, 1 month
Symptoms Vaccination
N = 162
No vaccination
N = 161 
Odds ratio
(95% CI)
x² 
Rash 11 (6.7) 2 (1.2) 5.76 (1.40-38.84) p = 0.0055
Pharyngitis 10 (6.1) 12 (7.4) 0.81 (0.33-1.97) p = 0.32
Arthralgia 17 (10.4) 14 (8.6) 1.23 (0.58-2.63) p = 0.29
Cervical lymphadenopathy 6 (3.7) 1 (0.6) 6.126 (0.89-143.3) p = 0.02
Myalgia 11 (6.7) 7 (4.3) 1.6 (0.60-4.49) p = 0.16
Paraesthesias 3 (1.8) 1 (0.6) 3.00 (0.31-79.94) p = 0.15
Temperature 0 0 \ \
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comparison has been performed with women in whom 
symptoms might occur for any other reason: this means 
that also our cases could have experienced such symp-
toms for different reasons. However, our analysis seems 
to confirm that a higher incidence of untoward effects 
directly linked to vaccination should not be expected. 
In our opinion, this experience shows that the vac-
cination proposal has a high acceptance rate and can be 
safe in the immediate postpartum, and that seronega-
tive women should be vaccinated after delivery with one 
dose of MMR before leaving the hospital [10]. One ad-
vantage of our approach is that now offering postpartum 
vaccination is a shared culture among health operators, 
physicians of territorial health service, and public and 
private obstetricians working in this area. All seronega-
tive women admitted to our hospitals during pregnancy 
have already been informed that vaccination will be of-
fered during postpartum and then most of them have 
already decided to accept it. Women who have rejected 
it have done to preconceived ideas about vaccinations 
in general. Likewise, the increase of information and 
education gained during pregnancy may allow women 
to avoid the risk of CRS in a future pregnancy.
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